ASCO22: Kidney Cancer research by Toni Choueiri, MD
New data on adjuvant pembrolizumab after kidney cancer surgery presented by Dana-Farber's Toni Choueiri, MD, at #ASCO22. KEYNOTE-564 shows prolonged distant metastasis-free survival and clinically relevant time to subsequent anticancer therapy and 2nd disease progression.
Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair ...
